Beit Jala Pharmaceutical Company (PEX:BJP)
Palestine
· Delayed Price · Currency is JOD 3.620
+0.020 (0.56%)
At close: Jan 13, 2026
PEX:BJP Income Statement
Financials in millions JOD. Fiscal year is January - December.
Millions JOD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 12.78 | 9.66 | 9.61 | 10.77 | 9.76 | Upgrade
|
| Revenue Growth (YoY) | 32.28% | 0.54% | -10.73% | 10.37% | 12.26% | Upgrade
|
| Cost of Revenue | 7.8 | 6.48 | 6.15 | 6.75 | 6.96 | Upgrade
|
| Gross Profit | 4.98 | 3.19 | 3.46 | 4.02 | 2.79 | Upgrade
|
| Selling, General & Admin | 1.66 | 1.26 | 1.3 | 1.66 | 1.69 | Upgrade
|
| Operating Expenses | 1.66 | 1.26 | 1.3 | 1.66 | 1.69 | Upgrade
|
| Operating Income | 3.32 | 1.92 | 2.16 | 2.35 | 1.11 | Upgrade
|
| Interest Expense | -0.05 | -0.11 | -0.11 | -0.12 | -0.09 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.27 | 0.06 | -0.1 | 0.12 | 0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.01 | - | 0.01 | 0.01 | 0.01 | Upgrade
|
| Pretax Income | 3 | 1.87 | 1.96 | 2.36 | 1.05 | Upgrade
|
| Income Tax Expense | 0.27 | 0.12 | 0.12 | 0.38 | 0.18 | Upgrade
|
| Net Income | 2.73 | 1.76 | 1.84 | 1.98 | 0.87 | Upgrade
|
| Net Income to Common | 2.73 | 1.76 | 1.84 | 1.98 | 0.87 | Upgrade
|
| Net Income Growth | 55.69% | -4.42% | -7.26% | 127.43% | 16.87% | Upgrade
|
| Shares Outstanding (Basic) | 7 | 7 | 7 | 7 | 7 | Upgrade
|
| Shares Outstanding (Diluted) | 7 | 7 | 7 | 7 | 7 | Upgrade
|
| Shares Change (YoY) | -0.01% | - | - | - | - | Upgrade
|
| EPS (Basic) | 0.39 | 0.25 | 0.26 | 0.28 | 0.12 | Upgrade
|
| EPS (Diluted) | 0.39 | 0.25 | 0.26 | 0.28 | 0.12 | Upgrade
|
| EPS Growth | 55.70% | -4.42% | -7.26% | 127.43% | 16.87% | Upgrade
|
| Free Cash Flow | 0.15 | 0.22 | 0.67 | 2.81 | 0.27 | Upgrade
|
| Free Cash Flow Per Share | 0.02 | 0.03 | 0.10 | 0.40 | 0.04 | Upgrade
|
| Dividend Per Share | - | 0.120 | 0.100 | 0.100 | 0.100 | Upgrade
|
| Dividend Growth | - | 20.00% | - | - | - | Upgrade
|
| Gross Margin | 38.96% | 32.99% | 36.00% | 37.31% | 28.63% | Upgrade
|
| Operating Margin | 25.99% | 19.91% | 22.45% | 21.87% | 11.35% | Upgrade
|
| Profit Margin | 21.39% | 18.17% | 19.11% | 18.40% | 8.93% | Upgrade
|
| Free Cash Flow Margin | 1.14% | 2.26% | 6.97% | 26.14% | 2.75% | Upgrade
|
| EBITDA | 6.29 | 2.6 | 3.26 | 3.31 | 2.12 | Upgrade
|
| EBITDA Margin | 49.24% | 26.95% | 33.90% | 30.70% | 21.69% | Upgrade
|
| D&A For EBITDA | 2.97 | 0.68 | 1.1 | 0.95 | 1.01 | Upgrade
|
| EBIT | 3.32 | 1.92 | 2.16 | 2.35 | 1.11 | Upgrade
|
| EBIT Margin | 25.99% | 19.91% | 22.45% | 21.87% | 11.35% | Upgrade
|
| Effective Tax Rate | 8.87% | 6.18% | 6.29% | 16.22% | 17.21% | Upgrade
|
| Advertising Expenses | - | 0.03 | 0.04 | 0.08 | 0.07 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.